Select your Market

Group Benefits from Global Diversification in a Challenging Environment

Group generated net sales of € 5.3 billion in the first quarter of 2023.

Key facts and Forecast

Results of Q1 2023   

  • Group net sales rise by 1.8% to € 5.3 billion  
  • New Healthcare products major growth drivers  
  • EBITDA pre down -2.6% to € 1.6 billion
  • Medium-term structural growth drivers intact 

Forecast for fiscal 2023   

  • Net sales: organic growth of 1% to 4%
  • Net sales excluding Covid-19-related business: organic increase of 4% to 7%
  • EBITDA pre: organic decline of ‑5% to stable at 0%
  • Negative foreign exchange effects on net sales and EBITDA pre of ‑5% to ‑2% expected

OVERVIEW: BUSINESS PERFORMANCE IN Q1 2023

 

Q1 2023              
(in € billion)

Change (in %, compared to Q1 2022)

Organic growth (in %, compared to Q1 2022)

Group net sales

5.3

1.8

0.8

EBITDA pre

1.6

-2.6

-1.7

Life Science sales

2.5

1.7

0.6

Healthcare sales

1.9

6.2

5.3

Electronics sales

0.9

-5.9

-7.1

Belén Garijo - Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

2023 will be a transition year for us. But our structural growth drivers remain intact.

Belén Garijo

Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

Recordings & Conference calls for the media and analysts

The conference call for the media and the conference call for analysts are available as a recording.

Related News

View All News
  1. Press Releases

    Q1 Results: Merck KGaA, Darmstadt, Germany, Benefits from Global Diversification ...

    Merck KGaA, Darmstadt, Germany generated net sales of € 5.3 billion in the first quarter of 2023. This corresponds to an increase of 1.8% over the year-earlier quarter (organically 0.8%).

    2023/05/11

Esther Döringer

Media Relations

Constantin Fest

Head of Investor Relations

+49 6151 72-5271

+49 6151 72 91-5271

Annual Reports Archive

Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more